Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for generalized anxiety disorder (GAD) were investigated in a clinical trial (NCT01766401 ClinicalTrials.gov). Participants (18-70 years, inclusive) who met Diagnostic and Statistical Manual of Mental Disorders, 4th ed., text revision, criteria for GAD were randomized (1:1) to placebo or flexible-dose vilazodone (20-40 mg/day) for 8 weeks of double-blind treatment. Primary and secondary efficacy parameters were changes from baseline to week 8 in Hamilton Rating Scale for Anxiety and Sheehan Disability Scale total scores, respectively. Analysis was based on a mixed-effects model for repeated measures approach on the intent-to-treat population. The intent-to-treat population comprised 395 patients (placebo=197, vilazodone=198); 77% completed the study. The least squares mean difference in change from baseline to week 8 in the Hamilton Rating Scale for Anxiety total score was statistically significant for vilazodone versus placebo [-1.50 (-2.96, -0.04), P=0.0438]. The mean change from baseline to week 8 in the Sheehan Disability Scale total score for vilazodone versus placebo was not statistically significant. Adverse events were reported in 60% of placebo-treated and 83% of vilazodone-treated patients. This was a positive clinical trial of 20-40 mg/day vilazodone versus placebo in the treatment of GAD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199 · cited 2×
“The significant between-group difference in favor of vilazodone on HAMD17 may be of interest as this study was conducted in a nondepressed or mildly depressed patient population, as indicated by baseline HAMD17 scores of ∼13 in both treatment groups (Zimmerman et al., 2013).”
BackgroundResultSareen, J., Cox, B. J., Afifi, T. O., de Graaf, R., Asmundson, G. J. G., ten Have, M., & Stein, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1249 · Cited by 824
Generalized anxiety disorder: prevalence, burden, and cost to society
Wittchen, H.-U. (2002) · Depression and Anxiety · doi:10.1002/da.10065 · Cited by 733 · cited 1×
“GAD, which often occurs comorbidly with major depression, is as seriously impairing as a major depressive episode (Wittchen, 2002).”
BackgroundBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 1×
“…(SNRIs; duloxetine, venlafaxine), benzodiazepines (alprazolam, diazepam, lorazepam), and SSRIs (citalopram, escitalopram, paroxetine, sertraline), in addition to the 5-HT1A receptor partial agonist, buspirone, and the anticonvulsant, pregabalin (Bandelow et al., 2012; Baldwin et al., 2014).”
BackgroundBandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Möller, H.-J., WFSBP Task Force on Mental Disorders in Primary Care, & WFSBP Task Force on Anxiety Disorders, O. A. P. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667114 · Cited by 428
Sexual Dysfunction, Depression, and the Impact of Antidepressants
Kennedy, S. H., & Rizvi, S. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819c76e9 · Cited by 338 · cited 1×
“As sexual dysfunction is a known effect of SSRI treatment (Kennedy and Rizvi, 2009), it is relevant that treatment with vilazodone and placebo produced similar effects on sexual function according to results from the CSFQ, and few sexual function TEAEs occurred in vilazodone-treated patients.”
ResultHu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0712 · Cited by 235 · cited 1×
“Sexual dysfunction, the most common complication of SSRI treatment in patients with depression (Baldwin, 2004), is also considered to be one of the most unacceptable side effects (Hu et al., 2004).”
Background
Cited by
Craske, M. G., & Stein, M. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30381-6 · Cited by 640
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
“009 223 221 Gommoll, b [93] 2015 SSRI 0.”
Evaluation of vilazodone for the treatment of depressive and anxiety disorders
Stuivenga, M., Giltay, E. J., Cools, O., Roosens, L., Neels, H., & Sabbe, B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1549542 · Cited by 24
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Thase, M. E., Edwards, J., Durgam, S., Chen, C., Chang, C.-T., Mathews, M., & Gommoll, C. P. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000180 · Cited by 11
Self-citation
Metadata
- Authors
- Gommoll, C., Forero, G., Mathews, M., Nunez, R., Tang, X., Durgam, S., & Sambunaris, A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2015-11
- Volume
- 30
- Issue
- 6
- Pages
- 297-306
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1155969651
- Cited by
- 25
- References
- 14
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. https://app.cochat.ai/papers/10.1097/yic.0000000000000096
- The paper
- Gommoll, C., Forero, G., Mathews, M., Nunez, R., Tang, X., Durgam, S., & Sambunaris, A. (2015). Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.